News

Lutetium-177 rosopatamab tetraxetan plus SOC therapies was safe and tolerable in patients with PSMA-positive mCRPC.

Unlike conventional radiation therapy systems, adaptive radiotherapy creates a new plan for each treatment session, allowing clinicians to deliver larger doses of radiation to tumors more safely.

Neha Vapiwala, MD, FACR, FASTRO, FASCO, unpacks notable updates from ASCO GU and discusses a trend toward individualized therapy in prostate cancer.

Marwan G. Fakih, MD, discusses the implications of the FDA approval of retifanlimab plus chemotherapy for the evolving role of immunotherapy in SCAC.

Researchers at Dana-Farber Cancer Institute show why SCLC stays out of reach of the immune system, even when cancer cells are vulnerable to immune attack.

Response to evorpacept plus zanidatamab was predicted by high levels of CD47 expression in patients with HER2-positive metastatic breast cancer.

Rachna T. Shroff, MD, MS, FASCO, discusses how this “sea change” has coincided with evolving considerations for frontline selection in pancreatic cancer.

Giuseppe Curigliano, MD, PhD, discusses the challenges of treatment sequencing in HER2-positive breast cancer with all the options currently available.

PD-L1 expression may signal worse outcomes with frontline osimertinib in EGFR-mutant metastatic NSCLC, highlighting potential prognostic value.

The FDA has issued a CRL for retifanlimab plus chemotherapy in metastatic NSCLC citing compliance issues at a third-party facility.

Andrew Hyland, PhD, of Roswell Park Comprehensive Cancer Center, received the 2026 John Slade Award from the Society for Research on Nicotine and Tobacco.

explains how the availability of neoadjuvant and adjuvant immunotherapy is reshaping treatment decisions in CSCC.

The FDA indications for tazemetostat in relapsed/refractory follicular lymphoma and epithelioid sarcoma are being voluntarily withdrawn.

The EC approved an indication extension for niraparib and abiraterone acetate dual-action tablets plus prednisone/prednisolone with ADT in BRCA1/2-mutated mHSPC.

The EMA has received a Type II variation application seeking the approval of teclistamab for relapsed/refractory multiple myeloma after 1 line of therapy.

Data from China showed relma-cel yielded durable responses in patients with relapsed/refractory mantle cell lymphoma.

Will the FDA approve T-DXd for HER2-positve early breast cancer with residual disease after HER2-targeted neoadjuvant therapy?

Continuing treatment with zenocutuzumab beyond disease progression was effective and safe in patients with advanced NRG1+ NSCLC.

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study evaluating the MET-directed ADC Temab-A vs SOC active surveillance in postadjuvant, ctDNA-positive CRC.

Mezigdomide plus carfilzomib and dexamethasone improved progression-free survival in relapsed/refractory multiple myeloma.

Giredestrant plus palbociclib did not yield a statistically significant PFS improvement in ER-positive/HER2-negative locally advanced or metastatic breast cancer.

The FDA has received a resubmitted sBLA for nogapendekin alfa inbakicept in BCG-unresponsive NMIBC with papillary-only tumors.

Peter WT Pisters, MD, received the Charles M. Balch, MD, Distinguished Service Award at the 2026 Society of Surgical Oncology Annual Meeting 

Jasleen Pannu, MBBS, explains how interventional pulmonologists guide timely molecular testing and treatment through lung cancer diagnosis, staging, and tissue acquisition.

Findings presented at the Miami Breast Cancer Conference support using T-DXd across a wide range of real-world patients in community cancer settings.